PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders.
Our lead programs are focused on Autism Spectrum Disorder (ASD).
Autism Spectrum Disorders are characterized by extreme versions of the processes that govern the ability to (1) focus attention, and (2) filter out sensory input. While these often bring with them a wide range of special abilities — including the ability to hyperfocus on specific tasks — they also can make normal everyday interactions and activities more challenging, not only for people with autism, but also for those around them, beginning with their families.
PaxMedica’s lead product in development may help eliminate, reduce, or modulate some of the more troublesome aspects of these processes. That opens the potential for people with autism to integrate their behavior with others more successfully and improve their lives. And that would be a significant advance for them and everyone they touch — families, friends, and the larger world around them.
We are building a robust pipeline of products targeting Autism Spectrum Disorder and related neurodevelopmental conditions.Learn More
Live on Tuesday, 9/12 at 3:00 PM (Eastern Standard Time)
Business Briefing: SIGNIFICANT PHASE 3 PAX-HAT-301 STUDY RESULTS; PROGRESSING TOWARD START OF MULTI-CENTEREDCLINICAL TRIALS IN ASD